8-K
Current Report
Viridian Therapeutics, Inc.\DE Filed Acc 0001590750-19-000040
Agreement ended · Results of operations · Exit or restructuring costs
- Item 1.02 Termination of a material definitive agreement
- Item 2.02 Results of operations and financial condition
- Item 2.05 Costs associated with exit or disposal activities
From the SEC's structured data for this filing
Loading mgen-q220198k.htm…